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130 (77%) BSI occurred during neutropenia and 21 (12%) during
GVHD. There was a significant decrease in Gram+/Gram- ratio over
time, from to 2.4 in 2004 to 1 in 2007, p=0.05. Staphylococci de-
creased from 37/68 (54%) in 2004-05 to 8/35 (23%) in 2006-07,
p=0.0001. Enterococcus faecalis/E.faecium ratio decreased from
4.5 in 2004 to 0.3 in 2007, p=0.05, but the number of isolates
per year did not change. The prevalence of E. coli among Gram-
negative rods increased from 3/15 (20%) in 2004 to 13/21 (62%)
in 2007, p=0.01. Oxacillin and, respectively, penicillin resistance
was 98% (44/45) for staphylococci and 64% (7/11) for viridans
streptococci. The number of ampicillin-sensitive enterococci de-
clined from 13/20 (65%) in 2004-05 to 6/20 (30%) in 2006-07,
p=0.05. P. aeruginosa susceptibility was 55%, 85% and 60% to cef-
tazidime, piperacillin/tazobactam and carbapenems, respectively.
Number of ESBL-producing bacteria remained stable: 18% (7/25) of
E. coli, 86% (6/7) of K. pneumoniae and 57% (4/7) of Enterobacter.
Fluoroquinolone-resistance was frequent, with only 19% (20/103)
of Gram-positive and 28% (19/69) of Gram-negative bacteria be-
ing sensitive. Overall mortality at 7 and 30 days after BSI was 11%
and 20% (19 and 34 out of 169). Pathogen type was the only vari-
able which significantly influenced 7-day survival, p=0.006. Mortal-
ity was the highest in case of P. aeruginosa (7/20, 35%), followed
by Candida (3/11, 27%), K. pneumoniae (1/7, 14%) and Enterococ-
cus (5/36,14%). Mortality at 30 days was influenced by phase of
underlying disease (remission or relapse), p=0.042.
Conclusions: BSI is frequent after allogeneic HSCT, particularly
during pre-engraftment phase. BSI etiology and antimicrobial resis-
tance change rapidly. Early mortality seems to depend on causative
pathogen.
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Introduction: Toxoplasma gondii is an intracellular protozoon,
which can cause disseminated disease in immunocompromised pa-
tients, with a high mortality rate.
Materials, Methods and Results: A case of toxoplasmosis is de-
scribed in 42-year-old woman, who underwent double cord-blood
transplantation for acute leukemia. The patient was seronega-
tive for T. gondii, whereas the serology status of graft was un-
known. On day +29, she developed grade II acute graft-versus-
host disease (GVHD) concerning the skin and liver, that responded
promptly to methylprednisolone (MP). On the same day, reacti-
vation of human-herpesvirus 6 (HHV-6) by PCR in the peripheral
blood was noticed, that responded to foscarnet. On day +43 her
temperature rose to 39°C with abdominal pain, headache and sen-
sor disturbances in palms and soles, without remarkable clinical
findings. Blood cultures for fungi, bacteria and PCR analysis for
viruses remained negative. Thoracic CT scan revealed a nodular
opacity in left upper field. Despite the prompt initiation of em-
piric therapy (meropenem, teicoplanin, canspofungin, voricona-
zole, foscarnet, pentamidine), on day +46 she had high fever, in-
creasing levels of transaminases, LDH and C-reactive protein, and
a biopsy proven relapse of aGVHD of the skin. On day +49 despite
high dose MP, the fever and maculopapular rash remained stable,
and pleural effusions, confusion and motor weakness ensued. Due
to persistent aplasia, bone marrow aspirate was performed and
T. gondii cysts were identified. PCR analysis from blood and mar-
row specimens confirmed the diagnosis. Antitoxoplasmic therapy
with pyrimethamine, clindamycin, azithromycin and folinic acid
prevention was immediately started; unfortunately, she deterio-
rated rapidly and died 2 days later with multiple organ failure.
Autopsy was denied.
Conclusions: In this case the source of toxoplasmosis was unclear
and the diagnosis could have been missed if bone marrow aspi-
rate was not performed. Transplant patients present a population
at risk for toxoplasmosis. Early detection of T. gondii by molecular
techniques, and prompt initiation of appropriate treatment may
prevent disseminated infection and fatal outcome.
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Background: Cytomegalovirus (CMV) is still a major cause of mor-
bidity and mortality in HSCT recipients, especially among those
who receive grafts from mismatched unrelated donors or umbilical
cord blood. Monitoring of these patients and guidance of preemp-
tive therapy is essential and points out the necessity of a suitable
laboratory marker.
Objective: We compared the pp65 Ag assay with the qualitative
and RealTime quantitative PCR in order to determine which detec-
tion method and in what blood compartment is better in terms of
sensitivity and specificity for the monitoring of HSCT recipients.
Methods: From 6/2003 to 2/2008 a total of 7248 EDTA-samples
were admitted to our lab for pp65 Ag and PCR. 5209 of these sam-
ples were drawn from 257 HSCT recipients from our transplant unit
that were weekly monitored for CMV infection by both pp65 Ag
and qualitative (n=901) or quantitative (n=4308) PCR in plasma or
PBL. The samples were classified into 4 groups depending on the
result of the pp65 assay. Group 1 (n=4645) counts for the pp65 neg-
ative samples, along with subgroup 1 (n=137) in which pp65 assay
was negative but concerns samples that preceded or followed pos-
itive antigenemia, Group 2 (n=161) corresponds to samples with
low pp65 values (1-5 cells), Group 3 (n=95) counts for samples with
>5 positive cells and Group 4 (n=171) consists of samples that the
assay was impossible due to low PBL count.
Results: Both PCR assays were positive in plasma and PBL in Group
3 samples. In Group the 2 qualitative PCR failed to detect CMV DNA
in plasma in 35.5% of the samples showing high false negatives. The
results were better when PBL was tested (10.7% false negatives).
Quantitative RT PCR was positive in all Group 2 and Group 3 sam-
ples in both blood compartments. In Group 1 samples both assays
presented detectable CMV DNA levels: 41% for the qualitative and
56% for the RT PCR method corresponded to patients that eventu-
ally became positive for pp65 Ag. CMV DNA load: the median VL
(copies/mL) in plasma and PBL was respectively: Group 1: 8.58 10
2 and 1.16 10 2, Group 2: 2.6 10 3 and 3.77 10 2, Group 3: 1.25 10
4 and 3.92 10 3.
Conclusions: To our knowledge quantitative RT PCR in plasma is
the suitable laboratory marker to monitor and guide preemptive
therapy in HSCT recipients due to extremely low false negatives
and its satisfying positive predictive value. Futhermore the VL in
plasma offers a good discriminating tool for the CMV infection sta-
tus of the patient.
